S&P 500   3,941.26 (-1.44%)
DOW   33,596.34 (-1.03%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
S&P 500   3,941.26 (-1.44%)
DOW   33,596.34 (-1.03%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
S&P 500   3,941.26 (-1.44%)
DOW   33,596.34 (-1.03%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
S&P 500   3,941.26 (-1.44%)
DOW   33,596.34 (-1.03%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
NASDAQ:PRVB

Provention Bio - PRVB Price Target & Analyst Ratings

$8.93
-0.01 (-0.11%)
(As of 12/6/2022 12:00 AM ET)
Add
Compare
Today's Range
$8.73
$9.19
50-Day Range
$4.34
$9.50
52-Week Range
$3.18
$9.85
Volume
820,116 shs
Average Volume
1.09 million shs
Market Capitalization
$778.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.40

Provention Bio Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Buy
Based on 6 Analyst Ratings

Consensus Analyst Price Target

$21.40
139.64% Upside
High Prediction$30.00
Average Prediction$21.40
Low Prediction$18.00
TypeCurrent
12/6/21 to 12/6/22
1 Month Ago
11/6/21 to 11/6/22
3 Months Ago
9/7/21 to 9/7/22
1 Year Ago
12/6/20 to 12/6/21
Consensus Rating
Buy
Buy
Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
6 Buy rating(s)
6 Buy rating(s)
7 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$21.40$19.00$18.33$17.75
Predicted Upside139.64% Upside197.03% Upside256.22% Upside163.00% Upside
Get Provention Bio Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for PRVB and its competitors with MarketBeat's FREE daily newsletter.


PRVB Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

PRVB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Provention Bio Stock vs. The Competition

TypeProvention BioMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.66
2.48
Consensus RatingBuyBuyHold
Predicted Upside140.45% Upside579.01% Upside15.79% Upside
News Sentiment RatingPositive News
Neutral News
Neutral News
MarketBeat
Community Rating
Outperform Votes
188
68.86%
Underperform Votes
85
31.14%
Avg. Outperform Votes
163
66.26%
Avg. Underperform Votes
83
33.74%
Avg. Outperform Votes
851
68.08%
Avg. Underperform Votes
399
31.92%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/21/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$16.00 ➝ $19.00+135.15%
11/18/2022Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$24.00 ➝ $30.00+271.29%
11/18/2022Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$14.00 ➝ $18.00+120.59%
11/18/2022Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$18.00 ➝ $22.00+177.43%
7/11/2022HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Ram Selvaraju
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy$25.00 ➝ $18.00+294.74%
4/1/2022Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
P. Agrawal
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight
11/23/2021Sumitomo Mitsui Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Outperform
11/23/2021UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Outperform
7/11/2021Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingHold$8.00+23.65%
(Data available from 12/6/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












PRVB Price Target - Frequently Asked Questions

What is Provention Bio's consensus rating and price target?

According to the issued ratings of 6 analysts in the last year, the consensus rating for Provention Bio stock is Buy based on the current 6 buy ratings for PRVB. The average twelve-month price prediction for Provention Bio is $21.40 with a high price target of $30.00 and a low price target of $18.00. Learn more on PRVB's analyst rating history.

Do Wall Street analysts like Provention Bio more than its competitors?

Analysts like Provention Bio more than other Medical companies. The consensus rating score for Provention Bio is 3.00 while the average consensus rating score for medical companies is 2.66. Learn more on how PRVB compares to other companies.

Do MarketBeat users like Provention Bio more than its competitors?

MarketBeat users like Provention Bio more than other Medical companies. 68.86% of MarketBeat users gave Provention Bio an outperform vote while medical companies recieve an average of 66.12% outperform votes by MarketBeat users.

Does Provention Bio's stock price have much upside?

According to analysts, Provention Bio's stock has a predicted upside of 190.68% based on their 12-month price targets.

What analysts cover Provention Bio?

Provention Bio has been rated by Chardan Capital, Jefferies Financial Group, Oppenheimer, and SVB Leerink in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:PRVB) was last updated on 12/6/2022 by MarketBeat.com Staff